Cancer diagnosis most often follows symptom onset and typically occurs in primary care settings. Improving the ability of clinicians to identify individuals who require urgent investigation into suspected cancer could support earlier diagnosis and improve outcomes. However, correct diagnosis remains challenging because general practitioners must manage symptoms early in their course, often in the presence of multiple evolving clinical features.

Symptomatic diagnoses often involve short episodes that resolve spontaneously without a clearly defined disease or specific treatment. In contrast, persistent symptoms are a clinically important concern that requires further evaluation, particularly in primary care settings.

Bladder cancer is the 10th most common cancer worldwide and the second most common urologic malignancy, with more than 550,000 new cases and more than 200,000 deaths annually, based on 2020 data. Early diagnosis is associated with improved survival rate. Timely detection remains difficult because presenting symptoms are common and are often attributed to benign conditions, such as urinary tract infections (UTIs) and benign prostatic disorders.

Symptom Patterns

UTIs occur in 30%-40% of individuals with bladder cancer in the year preceding diagnosis. Presentation with recurrent UTIs has been associated with a longer median diagnostic interval (83 days) than with visible hematuria (50 days). This difference suggests suboptimal adherence to referral guidelines in some individuals whose clinical features warrant rapid specialist evaluation for the prompt diagnosis of cancer.

There is considerable variability in the measures of diagnostic timeliness among patients with different cancer types, and much of this variability has been attributed to the different nature, frequency, and combination of presenting symptoms (the “symptom signature”) at each tumor site. This concept of symptomatic signature reflects the pattern and relative frequency of symptoms reported at presentations among individuals later diagnosed with a particular cancer.

Diagnostic difficulty correlates with the positive predictive value of a symptom for a given disease and is defined as the proportion of individuals with that symptom who have the disease. A single UTI presentation is associated with a low likelihood of cancer, while repeated presentations may show a higher probability.

Individuals with bladder cancer, particularly women, who present with UTIs or similar symptoms experience longer diagnostic delays, are less likely to be referred to a specialist, and present with a more advanced disease stage and poorer survival than those presenting with hematuria.

Risk Signals

The definition of recurrent UTIs is largely based on clinical consensus, and evidence on their effect on the risk for bladder cancer remains limited. Many individuals with recurrent UTI symptoms receive repeated courses of antibiotics with suboptimal follow-up in primary care and few follow-up visits.

A retrospective case-control study examined time intervals during which repeated infections most strongly signal risk for bladder cancer, quantified the probabilities associated with the number of episodes and observation intervals, and estimated the probability of cancer in individuals with recurrent infections and those with persistent irritative symptoms without confirmed infection.

An association between recurrent infections and the risk for bladder cancer was observed within the first 6 months, with the strongest effect observed in individuals with five or more infections during this period.

What to Look Out for in Clinical Practice

• Recurrent UTIs are associated with an increased risk for bladder cancer over 0-24 months compared with a single episode.
• The highest risk was seen in individuals with recurrent UTIs within 6 months, particularly those with five or more episodes of UTI, who showed an approximately 2.5-fold higher likelihood of developing bladder cancer than those with three episodes of UTI.
• A stronger dose-response relationship was seen in women. Despite the higher rates of recurrent UTIs in women, frequent infections within a 6-month timeframe should prompt clinicians to consider further diagnostic evaluation.
• The 6-month interval is the most clinically relevant timeframe for defining recurrent UTIs in the context of bladder cancer risk.

This story was translated from Univadis Italy, part of the Medscape Professional Network.